On 16 December 2014, orphan designation (EU/3/14/1385) was granted by the European Commission to Immodulon Therapeutics Ltd, United Kingdom, for heat-killed Mycobacterium obuense (whole cell) for the treatment of pancreatic cancer.

The sponsorship was transferred to Immodulon Therapeutics B.V., Netherlands, in August 2019.

Key facts

Active substance
Heat-killed Mycobacterium obuense (whole cell)
Disease / condition
Treatment of pancreatic cancer
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Immodulon Therapeutics B.V.
Rietveldlaan 35
9731 MJ Groningen
The Netherlands
Tel. +31 6 5181 9557

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating